FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to immunology and can be used to produce a stable immunogenic combined vaccine. Vaccine contains: a) inactivated rotavirus strain 116E (IRV; b) an antigen of inactivated type I, type II and type III inactivated poliovirus D (sabin) present in ratio of 40:8:32; c) diphtheria anatoxin antigen (DT; d) cell-free antigen Bordatella pertusis (aP), pertussis-related anatoxin (PT) and filament hemagglutinin (FHA; e) tetanus toxoid (TT) antigen; f) hepatitis B surface antigen (HbsAg; g) conjugate antigen Haemophilius influenza type b PRP-tt (Hib-PRP-tt; and h) 2-phenoxyethanol as a preserving agent. PH of the vaccine composition is in range of 6.5 to 7.2, in 0.5 ml. Protective antigens HBsAg, DT, TT and aP are adsorbed on aluminium phosphate, and IRV is adsorbed on aluminium hydroxide. This group of inventions also relates to a method of vaccination for preventing and treating infections of rotavirus, poliomyelitis, whooping cough, hepatitis B, Haemophilus influenzae, diphtheria and tetanus.
EFFECT: using the given group of inventions enables to obtain a stable for at least one year, heptavalent vaccine, where antigens in the vaccine do not affect each other, and the vaccine provides equal or higher effectiveness as compared to individual antigens.
7 cl, 12 tbl, 8 ex
